Delivery Order SPE2DB22D3301-SPE2DB25FZ0UM
- Not listed
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $17,361.60 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen auto-injectors on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price contract represents a competitively awarded delivery order with no set-aside designation, supporting federal medical procurement needs for military and veteran healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $6,612.18. This is a firm fixed price delivery order with no set-aside designation, issued competitively, and is scheduled for completion by September 10, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters is based. This...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 12, 2025, with a completion date of September 15, 2025. This competitive, non-set-aside contract represents a firm fixed-price delivery order for pharmaceutical supplies to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a $11,468.93 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a completion date of August 12, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The vendor will perform this work from its corporate office in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $20,413.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside competitive award represents a direct delivery of pharmaceutical supplies to support federal medical procurement needs. The contract was performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0UMDelivery Order
The Defense Logistics Agency awarded a $7,999.09 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 10, 2025, with completion scheduled for September 11, 2025. This competitive award, issued without set-aside designation, represents a firm fixed price delivery order for pharmaceutical supply to support federal medical procurement needs. The contract specifies performance in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and primary distribution hub. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle extending through December 2026 that enables global pharmaceutical support for military healthcare systems. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies an extensive portfolio of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical devices across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Dupixent is a biologic treatment for moderate-to-severe atopic dermatitis and other inflammatory conditions, reflecting the company's role in supplying specialty pharmaceutical products to military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.0k | 9/10/25 |